Benzinga | Apr 19, 2021 08:42AM EDT

Arena Pharmaceuticals To Present Data From Phase 2b ADVISE Trial During Late-Breaking Research Session At American Academy Of Dermatology Virtual Meeting Experience

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented during a late-breaking session at the American Academy of Dermatology Virtual Meeting Experience taking place April 23 - 25, 2021.